Glycobiology market

Q: Which is the leading product type segment in the market?

Enzymes is the leading product type segment in the market. Read more

Glycobiology Market, by Product Type (Instruments, Enzymes, Consumables, Reagents & Kits, and Others), by Application (Diagnostic Applications, Industrial Applications, Therapeutic Applications, Drug Discovery and Development, and Others), by End User (Research Laboratories, Hospitals, Diagnostic Centers, Biopharmaceutical Companies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Oct 2022
CMI3639
195 Pages
Excel & Pdf
Biotechnology

Summary

Glycobiology is the study of the composition, biosynthesis, biology, and evolution of saccharides, which are found in abundance in nature and are also known as carbohydrates, sugar chains, or glycans. Glycobiology has broad application in various sectors of fundamental study, biomedicine, and biotechnology. Glycans are essential biomolecules, they can be considered as simple monosaccharides, but they can also form more complex structures such as natural glycoconjugates in which sugar moieties are attached to proteins or lipids.

Global glycobiology market is estimated to be valued at US$ 1,568.73 million in 2022 and is expected to exhibit a CAGR of 12.9% during the forecast period (2022-2030).

Figure 1. Global Glycobiology Market Share (%), by Product Type, 2022

Increasing prevalence of cancer is expected to drive growth of the glycobiology market.

Glycobiology systems and tools such as enzymes, instruments, reagents and kits among others can be used for discovering drug targets, biomarkers and designing immunotherapy for cancer. Thus, the increasing prevalence of cancer is expected to drive the market growth over the forecast period. For instance, according to data provided by National Cancer Institute, there were reportedly 16.9 million cancer survivors as of January 2019 in the U.S. Moreover, according to the same source up to 2030, there are expected to be 22.2 million cancer survivors and it is expected that by 2040, there would be 16.4 million cancer-related deaths and 29.5 million new instances of cancer each year.

Figure 2. Global Glycobiology Market Share (%), by Region, 2022

Increasing launches of glycobiology products by biopharmaceutical companies such as instruments, reagents & kits are expected to drive market growth during the forecast period.

The significance of glycan changes in healthy and pathological states is being investigated by scientists, who are also looking at tumor growth, viral capture, and medication discovery. Thus the increasing use of glycan instruments, reagents, and kits such as immunofluorescence kit for detection of glycan expression in tissue is expected to drive the market growth over the forecast period. For instance, in July, 2022, Vector Laboratories a company providing life science products, announced the launch of the product Glysite Scout Glycan Screening Kit. These immunofluorescence (IF) kits are fully integrated for detection of glycan expression in tissue sections and support profiling and characterization of complex glycans in biological systems. Glysite Scout Glycan Screening Kit enables researchers to understand the importance of glycomics in samples for post-translational protein modifications and association with disease biomarkers.

Glycobiology Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 1,568.73 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	12.9%	2030 Value Projection:	US$ 4,153.76 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Product Type: Instruments, Enzymes (Glycosidase (Heparinase, Chitinase, Acetylgalactosaminidase, PNGase, Chitobiase, Others (Hyaluronidase , Hexosaminidase)), GlcNAc Transferases (Acetylglucosaminyltransferase, Exostosin, Other (Glucosaminyl Transferase, Glucuronyltransferase)), GalNAc Transferases (Polypeptide GalNAc Transferase, GANLTL, Others (GD2 Synthase,B3GANLT)), Fucosyl Transferases, Galactosyl Transferases, Carbohydrate Kinases, Others ( Pentosyl Transferase, Nuraminidases)), Consumables, Reagent & kits By Application: Diagnostic Application, Industrial Application, Therapeutic Application, Drug Discovery and Development, Others By End User: Research Laboratories, Hospitals, Diagnostic Centers, Biopharmaceutical Companies, Others
Companies covered:	Tracxn Technologies Limited, Agilent Tecnologies, Inc., Blirt.eu, Takara Bio Inc., Bio-Techne, Bruker Corporation, Thermo Fisher Scientific Inc., Shimadzu Corporation, New England Biolabs., Waters.co., Merck KGaA, Palleon Pharmaceuticals, Asparia Glycomics, RayBiotech Life,Inc., Z Biotech,LLC., Chemily Glycoscience, Lectenz Bio, 2BScientific , and Glycodiag.
Growth Drivers:	Increasing prevalence of cancer Increasing use of glycan systems and tools for detection and treatment of disease
Restraints & Challenges:	Inaccuracy in measuring total structure of glycans

Global Glycobiology Market– Impact of Coronavirus (COVID-19) Pandemic

According to the World Health Organization (WHO), the first identifiable COVID-19 case was detected in Wuhan Province, China in December 2019, and a global emergency was declared on 30 January 2020.

The COVID-19 impact created opportunity in the field of glycobiology, owing to its application in research activities and production of antiviral vaccines. Glycans are involved in various initiation and regulatory processes in living cells. Coronaviruses are glycosylated enveloped viruses that can be used to produce antiviral vaccines against COVID-19 infection. Thus, the increasing demand for producing antiviral vaccines due to the COVID-19 pandemic can be expected to drive the glycobiology market growth.

However, the COVID-19 pandemic and lockdown caused a disruption in supply chains and transportation of raw materials and drugs.

Global Glycobiology Market: Key Developments

In January, 2022, the Iceni Glycoscience, a company with expertise in glycoscience (carbohydrate chemistry and biology), launched a new in-house research and drug development program focused on glycoscience and glycoengineering.

In July, 2022, Ludger, a company conducting research and development in glyco technology, announced the pre-launch of three Lewis X glycan standards CN-A2G2F2-20U, CN-A2[3]G1F1-20U, CN-A2[3]G1-20U. Lewis X (Lex) is a fucosylated trisaccharide glycan epitope distributed in eukaryotes and certain bacteria. This carbohydrate epitope has been found to play a role in many physiological and pathological processes such as pathogenesis of diseases. Carbohydrate epitope is up regulated in various cancers such as pancreatic, breast, colon, and lung tumors, plays an important role in cell-cell interactions, and has been found in infectious bacteria such as Helicobacter pylori.

Global Glycobiology Market: Restraint

The major factor that hinders growth of the global glycobiology market includes inaccuracy in measuring total structure of glycans due to variability in susceptibility to hydrolysis of different bonds, variability in degradation of individual saccharides, or lack of specificity or sensitivity in the assay such as immunotherapy assay.

Key Players

Major players operating in the global glycobiology market include Tracxn Technologies Limited, Agilent Tecnologies, Inc, Blirt.eu, Takara Bio Inc., Bio-Techne, Bruker Corporation,Thermo Fisher Scientific Inc., Shimadzu Corporation , New England Biolabs., Waters.co., Merck KGaA , Palleon Pharmaceuticals ,Asparia Glycomics, RayBiotech Life, Inc., Z Biotech, LLC., Chemily Glycoscience, Lectenz Bio, 2BScientific , and Glycodiag.

Table of Content

Table of Contents

*Browse 36 market data tables and 38 figures on "Global Glycobiology Market” - Global forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global glycobiology market during the forecast period (2022-2030)?

The global glycobiology market size is estimated to be valued at US$ 1,568.73 million in 2022 and is expected to exhibit a CAGR of 12.9% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increasing prevalence of cancer and increasing use of glycans and tools for detection and treatment of disease are expected to drive the market growth.

Which is the leading product type segment in the market?

Enzymes is the leading product type segment in the market.

What are the key factors hampering growth of the market?

The major factor hampering growth of the market include its inaccuracy in measuring structures of glycans.

Which are the major players operating in the market?

Major players operating in the market include Tracxn Technologies Limited, Agilent Tecnologies,Inc., Blirt.eu, Takara Bio Inc., Bio-Techne, Bruker Corporation, Thermo Fisher Scientific Inc.,Shimadzu Corporation, New England Biolabs., Waters., Merck KGaA, Palleon Pharmaceuticals, Asparia Glycomics, RayBiotech Life, Inc., Z Biotech, LLC., Chemily Glycoscience, Lectenz Bio, 2BScientific, and Glycodiag.